NanoLogix to Begin Commercialization of BioNanoPore and BioNanoFilter Diagnostic Kits

NanoLogix, a biotechnology company specializing in the rapid detection of harmful bacteria, is all set to bring its BioNanoFilter (BNF) and BioNanoPore (BNP) diagnostic kits to the market under FDA 510K-exempt status.

To shorten bacterial detection time, samples grown on the NanoLogix BNP membrane can be moved to the staining plate. (photo: Business Wire)

The Petri-based BNP detection kit will be the first product to be commercialized using TSA media. Other nutrient media will be offered upon special order. According to recently concluded independent third-party research, BNP diagnostic kits are 2-10 folds quicker in detecting live bacteria when compared to conventional techniques.

NanoLogix plans to introduce its BNF technology to the marketplace following the rolling out of its BNP technology. As per third-party research documents, BNF technology is 18-72 folds quicker when compared to traditional detection and identification techniques. NanoLogix also intends to develop tailored test kits for client partners and specific applications.

NanoLogix will also start sales of traditional TSA Petri plates. The company will offer its TSA Petri plates and BNP kits in its proprietary inert-gas charged vacuum Flat Packs. According to a key third-party laboratory, these Flat Packs have demonstrated shelf life of one year when stored under standard conditions, compared to conventional Petri plates’ three-month shelf life.

The two independent third-party organizations have submitted their study results utilizing NanoLogix technology to key peer-reviewed medical technology journals for publication. The first submission describes the utilization of NanoLogix BNF test kits and final results of a Group B Streptococcus (GBS) clinical trial involving 356 pregnant patients conducted at the University of Texas Health Science Center - Houston. The second submission discusses the results of NanoLogix BNP test kits five-day detection of live Tuberculosis. Conventional culture takes 21-28 days to deliver results.

Source: http://www.nanologix.com

Will Soutter

Written by

Will Soutter

Will has a B.Sc. in Chemistry from the University of Durham, and a M.Sc. in Green Chemistry from the University of York. Naturally, Will is our resident Chemistry expert but, a love of science and the internet makes Will the all-rounder of the team. In his spare time Will likes to play the drums, cook and brew cider.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoLogix. (2019, February 12). NanoLogix to Begin Commercialization of BioNanoPore and BioNanoFilter Diagnostic Kits. AZoNano. Retrieved on September 29, 2020 from https://www.azonano.com/news.aspx?newsID=25430.

  • MLA

    NanoLogix. "NanoLogix to Begin Commercialization of BioNanoPore and BioNanoFilter Diagnostic Kits". AZoNano. 29 September 2020. <https://www.azonano.com/news.aspx?newsID=25430>.

  • Chicago

    NanoLogix. "NanoLogix to Begin Commercialization of BioNanoPore and BioNanoFilter Diagnostic Kits". AZoNano. https://www.azonano.com/news.aspx?newsID=25430. (accessed September 29, 2020).

  • Harvard

    NanoLogix. 2019. NanoLogix to Begin Commercialization of BioNanoPore and BioNanoFilter Diagnostic Kits. AZoNano, viewed 29 September 2020, https://www.azonano.com/news.aspx?newsID=25430.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit